Background: Benzydamine, a non-steroidal anti-inflammatory drug (NSAID) in use for more than four decades, has been reported to cause photosensitivity.
Benzydamine (CAS number 642-72-8) is an indazole non-steroidal anti-inflammatory drug (NSAID) that has analgesic, anti-inflammatory, and antipyretic properties and has been widely used across Europe for nearly four decades (1) . Benzydamine is available as a mouth wash for the relief of sore throats, as an antiseptic vagina douche, and as an anti-inflammatory cream and gel to treat soft tissues (1) (2) (3) . Recently, benzydamine was formulated in a muco-adhesive gel designed for oral ulcers and for radiation-induced mucositis of the oral, rectal, or vaginal mucosa in cancer treatment (4, 5) .
Photoallergic contact dermatitis from topical and systemic benzydamine is known (1-3, 6, 7 ). Since July 2006 after diagnosing a case of cheilitis as a manifestation of photoallergic contact dermatitis from benzydamine, this NSAID has been included in our photoallergen patch test series and nine additional cases of photoallergic contact dermatitis have been diagnosed.
Patients and Methods
During a 3-year period (2006) (2007) (2008) , 74 patients (53 females/21 males) with photodermatoses or facial dermatitis with aggravation following sun exposure were patch tested with an extended baseline series and photopatch tested with a photoallergen series that included sunscreens, salicylanilides and other disinfectants, phenothiazines, and NSAIDs including benzydamine (1 and 5% petrolatum (pet.) from Bial-Aristegui ® ). In suspicious cases, patients were also tested with the drug 'as is'. Allergens were applied in duplicate and irradiation of one set was performed on D2 with 5 J/cm 2 of UVA (Waldman ® 7001K). Readings were performed at D2, within 30 min after irradiation and at D4, according to ICDRG guidelines.
Results
A total of 10 patients (six females/four males), aged between 21 and 84 (mean age 64.9 years) were diagnosed as photoallergic contact dermatitis from benzydamine. In nine patients there was a subacute, pruriginous cheilitis, with erythema and scaling on the lower lip in all patients and superficial erosions in four patients (Fig. 1) . Eczema extended to the chin in seven patients, to the malar regions in three and was associated with erythema or eczema on the dorsum of the hands and forearms in two patients. Lesions were recurrent and, for two patients, had been occurring for more than 1 year. For 6 months, one patient had a severe lichenified eczema of the face, neck and the 'V' area of the upper chest, forearms, and dorsum of the hands (Fig. 2) .
All patients showed positive photopatch tests (+ to +++) to benzydamine tested at 1 and 5% and to benzydamine containing drugs (+ or +++) ( Table 1) . No reactions were observed on nonirradiated area to these allergens (Fig. 3) . Additional positive reactions were observed to fragrance mix I and Myroxylon pereirae (one patient) and nickel (three patients) ( Table 1) .
In the nine patients who had cheilitis, their histories showed long-term regular gargling with an oral antiseptic solution containing 1.5% benzydamine (Tantum verde ® , Lepori Laboratories, Lisbon, Portugal). Six of these patients had oral prostheses. Two younger patients used the solution after the fitting of an orthodontic device and their cheilitis began within 2 months. An older patient with the most extensive lesions had regularly applied a topical gel containing 3% benzydamine (Momen ® gel, Lepori Laboratories, Lisbon, Portugal) to his wife's back, for about 8 months. Two patients had been on photoactive systemic drugs (amiodarone and hydrochlorothiazide) for more than 2 years and they 
C, chin; F, forearms; H, hands; LE, lichenified eczema on photo-exposed areas; L, lower lip; M, malar region; NT, not tested. continued with no change in their doses. Lesions disappeared within a few days/weeks after benzydamine discontinuation, with no case of persistent photosensitivity. Therefore, all the reactions were considered relevant. Also, none of the other 64 patients photopatch tested with benzydamine had a positive result.
Discussion
Benzydamine has been shown to have phototoxic properties in vitro and to cause both phototoxicity and photoallergy (8) . In this study, positivity of the photopatch test with benzydamine at 1% pet., the absence of reactions in the other 64 patients who were photopatch tested at 5% pet. during this period, suggest these reactions are mainly photoallergic. Also, they were all considered relevant, with rapid improvement on drug discontinuation. The use of the gargling solution may explain the main localization on the lower lip and chin.
Although benzydamine is widely used (1, 3, 7) and it is a known photosensitizer, with several published cases in the 1980s and 1990s (9, 10) , even at our clinic (6) there are few recent reports of photoallergic contact dermatitis from benzydamine (2, 3, 11) . This may be because of the unusual presentation which does not suggest photosensitivity; the great majority of our patients presented with dermatitis involving mainly the lower lip and chin. Photoallergic contact dermatitis from benzydamine has presented as hand dermatitis from using a vaginal douche (2) . Therefore, UV-irradiation of the patch tests with the mouth wash products used by the patient in cases of cheilitis is not the usual practice. As a result of its widespread use as a mouth wash, we suggest benzydamine should be included in a photopatch test series for patients being investigated for cheilitis.
Under-reporting of photosensitivity from benzydamine may also occur, because this NSAID is not part of most photoallergen series, and without a good history of benzydamine use it may be missed. In a recent study from Spain, where benzydamine was included in a photopatch testing series, it was the second most frequent photoallergen, after ketoprofen (12) and, in a recent report from our department, benzydamine, tested only during the latter years of the study, was one of the main photoallergens, after piroxicam and promethazine (6) .
Cross-reactions with other NSAIDs have been suggested in one case (7), but, even though we did not test indomethacin, none of our patients reacted to other NSAIDs tested (ketoprofen, naproxen, ibuprofen, piroxicam, tenoxicam, and diclofenac).
Percutaneous or peroral absorption of this NSAID may have caused lesions at distant sites, as observed in four of our patients. There is a possibility that connubial photoallergic contact dermatitis as described for another NSAID, namely for ketoprofen (13, 14) , may occur.
